Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults

NCT ID: NCT00094718

Last Updated: 2013-01-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-02-28
• Study Completion Date: 2005-04-30

Brief Summary

West Nile (WN) virus infection is an emerging disease; WN infection may lead to paralysis, coma, and death. The purpose of this study is to test the safety of and immune response to a WN vaccine in healthy adults. The vaccine is based on a live attenuated vaccine developed against dengue virus.

Detailed Description

WN is widely distributed in Africa and Europe, where it is usually associated with mild illness. In the United States, WN is considered a public health threat because severe illness caused by WN infection has caused paralysis, coma, and death, especially in the elderly. This study will evaluate the safety and immunogenicity of a live attenuated chimeric virus, WN/DEN4-3'delta30, which is derived from the DEN4 dengue virus and wild-type WN serotypes.

This study will last 180 days. Participants in Cohort 1 will be randomly assigned to receive the lowest dose of WN/DEN4-3'delta30 or placebo at study entry. Cohort 2 will begin only after safety review of all participants in Cohort 1. Participants in Cohort 2 will receive a higher dose of WN/DEN4-3'delta30 or placebo. Cohort 3 will begin only after safety review of all participants in Cohort 2. Participants in Cohort 3 will receive the highest dose of WN/DEN4-3'delta30 or placebo. Immediately after receiving their injections, participants will be observed for 30 minutes for immediate adverse reactions.

After vaccination, participants will be asked to monitor their temperatures every day for 16 days and on Day 19. Study visits will occur every other day after vaccination until Day 16, followed by 5 additional visits at selected days through Day 180. Blood collection and a targeted physical exam will occur at each study visit. Some participants will be asked to undergo a skin biopsy or additional blood collection at selected visits.

Conditions

West Nile Fever Encephalitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

1

One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10\^3 PFU dose) into the deltoid region of either arm.

Group Type: EXPERIMENTAL

WN/DEN4-3'delta30

Intervention Type: BIOLOGICAL

Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)

2

One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10\^4 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 1 are analyzed.

Group Type: EXPERIMENTAL

WN/DEN4-3'delta30

Intervention Type: BIOLOGICAL

Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)

3

One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10\^5 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 2 are analyzed.

Group Type: EXPERIMENTAL

WN/DEN4-3'delta30

Intervention Type: BIOLOGICAL

Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)

4

One subcutaneous vaccination with placebo vaccine into the deltoid region of either arm.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

Placebo for WN/DEN4-3'delta30 vaccine

Interventions

WN/DEN4-3'delta30

Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)

Intervention Type: BIOLOGICAL

Placebo

Placebo for WN/DEN4-3'delta30 vaccine

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Willing to be followed for the duration of the study
• Willing to use acceptable methods of contraception
• Good general health

Exclusion Criteria

• Clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease
• Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the ability of the volunteer to understand and cooperate with the study
• Hematologic disease
• History of migraine headaches
• History of encephalitis
• Alcohol or drug abuse within 12 months prior to study entry
• History of severe allergic reaction or anaphylaxis
• Emergency room visit or hospitalization for severe asthma within 6 months prior to study entry
• HIV-1 infected
• Hepatitis C virus infected
• Hepatitis B surface antigen positive
• Known immunodeficiency syndrome
• Use of corticosteroids or immunosuppressive drugs within 30 days of study entry. Participants who have used topical or nasal corticosteroids are not excluded.
• Live vaccine within 4 weeks prior to study entry
• Killed vaccine within 2 weeks prior to study entry
• Blood products within 6 months prior to study entry
• Participation in another investigational vaccine or drug trial within 60 days of starting this study, or while participating in this study
• Previously received a licensed or experimental yellow fever, tick-borne encephalitis, or dengue vaccine
• Surgical removal of spleen
• History of West Nile encephalitis
• History of dengue virus infection or other flavivirus infection (e.g., yellow fever virus, St. Louis encephalitis, West Nile virus)
• Other condition that, in the opinion of the investigator, would affect the participant's participation in the study
• Pregnancy or breastfeeding

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Johns Hopkins Bloomberg School of Public Health

OTHER

Sponsor Role: collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Anna Durbin, MD

Role: PRINCIPAL_INVESTIGATOR

Center for Immunization Research, Johns Hopkins School of Public Health

Locations

Johns Hopkins School of Public Health

Baltimore, Maryland, United States

Vanderbilt University School of Medicine

Nashville, Tennessee, United States

Countries

United States

References

Chang GJ, Kuno G, Purdy DE, Davis BS. Recent advancement in flavivirus vaccine development. Expert Rev Vaccines. 2004 Apr;3(2):199-220. doi: 10.1586/14760584.3.2.199.

Reference Type: BACKGROUND

PMID: 15056045 (View on PubMed)

Lai CJ, Monath TP. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv Virus Res. 2003;61:469-509. doi: 10.1016/s0065-3527(03)61013-4.

Reference Type: BACKGROUND

PMID: 14714441 (View on PubMed)

Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, Marchesani R, Knauber M, Wells KH, Arroyo J, Guirakhoo F. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002 Jan 15;20(7-8):1004-18. doi: 10.1016/s0264-410x(01)00457-1.

Reference Type: BACKGROUND

PMID: 11803060 (View on PubMed)

Pletnev AG, Claire MS, Elkins R, Speicher J, Murphy BR, Chanock RM. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology. 2003 Sep 15;314(1):190-5. doi: 10.1016/s0042-6822(03)00450-1.

Reference Type: BACKGROUND

PMID: 14517072 (View on PubMed)

Pugachev KV, Guirakhoo F, Trent DW, Monath TP. Traditional and novel approaches to flavivirus vaccines. Int J Parasitol. 2003 May;33(5-6):567-82. doi: 10.1016/s0020-7519(03)00063-8.

Reference Type: BACKGROUND

PMID: 12782056 (View on PubMed)

Other Identifiers

H.22.04.10.06.A1

Identifier Type: -

Identifier Source: secondary_id

CIR 206

Identifier Type: -

Identifier Source: org_study_id